Event overview

...Breaking News...

Ian Abercrombie, European Director, Genzyme has joined our speaker faculty to deliver the keynote presentation on

Bringing a Orphan Niche Indication to Market: Key Insights from a Success Story.

More details to follow soon. Check out full speaker line up

This conference brings together oncology medical directors with business unit heads and marketing directors.  Those involved with launching and marketing Oncology will discover answers to the most pressing issues from pricing to strategy and market access to marketing to different stakeholders.

Check out a few of our speakers joining the European Oncology elite:

	Ian Abercrombie European Director, Genyme		Robert Day, Head of the Oncology Business Unit, UK, Pfizer
	Andrea Bracco, International Director of Market Access, Amgen		Yasmina Eroglu, Head of Marketing oncology, EEMEA, Novartis
	Christopher Teale, Global Director Pricing & Market Access, AstraZeneca		Jeroen van Dijk, Director of Oncology, Roche Nederland
	Ulf Staginnus, Head Pricing, Health Economics and Outcome Research Europe, Novartis		Boyka Stoykova, Health Economist, Wyeth
	Uday Bose, European Marketing Director, gsk		Jerome Moreau, Business Unit Director - Oncology, Cephalon
	David Perry, VP Global Clinical & Medical Affairs, Baxter		Eckart Knipping, International Marketing Director Oncology, GE Healthcare

Click Here to register your place today

The conference will enable you to:

• Understand how budget holders and healthcare systems view value and what makes a payer reject a drug for approval
• Understand the impact of innovative pricing and access structures for oncology: efficacy guarantees; risk-sharing with payers; price caps
• Understand the models, opportunities, risks and value of Phase IV strategies in oncology to reduce risk in market access
• Beyond QALY: learn how to prove value to the most demanding of reimbursement agencies
• Learn how to develop insight into payers, KOLs and budget managers to unify into a compelling proposition for prescribers
• Find out how the oncology environment will change by 2020 and how to adapt to a competitive oncology marketplace

Find out more on the PDF brochure